Unibar secures European patent for CapsiClear, targeting glaucoma and dry eye markets

The Unibar Corporation reveals it has received a European patent for CapsiClear, a capsanthin-rich carotenoid extract to support eye health. The patent covers CapsiClear’s use in reducing intraocular pressure associated with multiple types of glaucoma, including normal tension and primary open-angle glaucoma.

The patent applies across key European markets, including France, Germany, Italy, Spain, the UK, and several others. The company highlights that the patent positions it to expand the reach of its flagship ingredient amid growing demand for clinically validated eye health solutions.

“This European patent for CapsiClear underscores our long-standing commitment to best-in-class eye health research,” says Sevanti Mehta, president of Unibar. “This decision validates the innovation behind Unibar’s portfolio and our continued efforts to deliver effective, natural solutions for eye wellness backed by both modern science and ancient tradition.”

Plant-based eye health

CapsiClear is derived from Capsicum annum, is standardized to 50% capsanthin, and has demonstrated efficacy in managing intraocular pressure within the normal range, according to clinical research. The product also targets dry eye, a condition affecting an estimated 10% to 30% of adults in Europe, with prevalence rising due to increased screen time and environmental stressors.

Unibar stresses that the ingredient has shown potential to support tear production and maintain tear film stability, addressing hydration and comfort challenges linked to dry eye. Risk factors range from aging and reduced sleep to screen exposure.

Doug Lynch, CEO of MarketWell Nutrition and commercial representative for Unibar, says the patent will help introduce CapsiClear to its global partners.

“Patented, market-ready CapsiClear will bring true product differentiation to all our brand partners,” he notes.

An eye toward global expansion

The patent comes as Unibar prepares to increase engagement with formulators and brand partners at industry events this fall. The company says CapsiClear is ideal for use in dietary supplements aimed at eye health where clinically supported and plant-derived ingredients are in demand.

It also underscores that dry eye and glaucoma remain under-addressed segments in many parts of the supplement industry, despite rising prevalence and their impact on quality of life. CapsiClear’s new intellectual property protection adds to the growing list of proprietary ingredients aimed at addressing this market gap through non-pharmaceutical approaches.